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Background: Antiangiogenic treatment may change the tumor microenvironment and hence influence the effect
of conventional therapies. The potential of diffusion weighted magnetic resonance imaging (DW-MRI) and dynamic
contrast enhanced MRI (DCE-MRI) in assessing microenvironmental effects of sunitinib treatment was investigated
in this preclinical study.
Methods: Sunitinib-treated and untreated A-07 tumors were subjected to DW-MRI and DCE-MRI, and parametric
images of ADC and Ktrans were produced. Microvascular density, hypoxic fraction, and necrotic fraction were
assessed from immunohistochemical preparations, and tumor interstitial fluid pressure (IFP) was assessed with probe
measurement.
Results: Sunitinib-treated tumors showed reduced microvascular density, increased hypoxic fraction, increased necrotic
fraction, increased ADC, and reduced Ktrans, but did not differ from untreated tumors in growth rate and IFP.
Conclusions: Sunitinib treatment affected the tumor microenvironment without affecting tumor size. DW-MRI and
DCE-MRI were sensitive to the sunitinib-induced changes in the tumor microenvironment.
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Several antiangiogenic drugs are being investigated,
including endogenous inhibitors of angiogenesis [1],
monoclonal antibodies against pro-angiogenic factors
or their receptors [2,3], and small molecule tyrosine
kinase inhibitors which may target multiple pro-angiogenic
receptors [4]. The antiangiogenic agents are generally
not cytotoxic, and treatment-induced reductions in tumor
size often appear late compared to vascular effects [5].
It is therefore recognized that functional parameters
are more appropriate than tumor size for evaluating
early effects of antiangiogenic treatment [6].
Antiangiogenic therapy may inhibit tumor growth
significantly when used as a single treatment modality,
but the therapeutic benefit may be even greater when used
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stated.such as radiation and chemotherapy [7]. Tumor response
to radiation and chemotherapy can be significantly
affected by the tumor microenvironment. Tumors with
extensive hypoxia are more resistant to radiation and
some forms of chemotherapy, and elevated interstitial
fluid pressure (IFP) may reduce the uptake of chemo-
therapeutic drugs [8,9]. Antiangiogenic treatment has
been reported to improve oxygenation and reduce IFP
in some tumor models [2,3] and to induce hypoxia in
others [10,11]. The reasons for these different effects
are not clear, but the effects have important implications
for combination therapies. Careful monitoring of the
tumor microenvironment during antiangiogenic treatment
may help to optimize the timing of combination therapies.
Tumor response to antiangiogenic treatment has been
evaluated with diffusion weighted magnetic resonance
imaging (DW-MRI) and dynamic contrast-enhanced MRI
(DCE-MRI) [6,12]. DW-MRI is sensitive to the Brownian
motion of water molecules which is restricted by
cell membranes and extracellular fibers in tissues [12].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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to quantify DW-MRI data, and this parameter has
been shown to reflect cell density and to be sensitive
to necrotic tissue in untreated tumors [12,13]. Moreover,
both reductions and increases in tumor ADC have
been reported after antiangiogenic treatment [14,15].
In DCE-MRI, the uptake of a paramagnetic contrast
agent is studied by imaging tumors before and multiple
times within a few minutes after the injection of the
contrast agent. The transfer rate constant, Ktrans, can
be estimated by using the generalized pharmacokinetic
model of Tofts to analyze DCE-MRI series [16]. Ktrans
generally reflects blood perfusion and the vessel perme-
ability - vessel surface area product [17]. When using
low molecular weight contrast agents like Gd-DTPA
(550 Da), Ktrans has been shown to reflect blood perfusion
in untreated tumors with high vessel permeability [18].
Reductions in Ktrans or Ktrans -related parameters have
been reported in most studies evaluating tumor response
to antiangiogenic agents with DCE-MRI [6]. A weakness
in many of the studies evaluating tumor response to
antiangiogenic treatment with DW-MRI and/or DCE-
MRI is that treatment-induced effects on the tumor
microenvironment were not assessed with non-MR
techniques. Consequently, it is not always clear how
the changes in MR-derived parameters were related to
the tumor microenvironment.
Sunitinib is a small molecule tyrosine kinase inhibitor
which targets vascular endothelial growth factor receptors
1-3 (VEGFR-1, -2, and -3), platelet-derived growth factor
receptors α-β (PDGFR-α and PDGFR-β), stem cell growth
factor receptor (c-KIT), and fms-like tyrosine kinase
receptor 3 (FLT 3) [19]. Sunitinib has been shown to
prolong progression-free and overall survival in patients
with imatinib-refractory gastrointestinal stromal tumor,
metastatic renal cell carcinoma, and progressive, well-
differentiated pancreatic neuroendocrine tumor in clinical
phase III trials, and has been approved by the US Food
and Drug Administration for these indications [20-22].
In the current study we evaluated the effect of sunitinib
treatment on the tumor microenvironment by using
histological techniques to assess microvessels, tumor
hypoxia, and tumor necrosis and probe measurement to
assess tumor IFP. We also evaluated the effect of sunitinib
treatment with DW-MRI and DCE-MRI. We report
that sunitinib treatment increased ADC and reduced
Ktrans, reflecting sunitinib-induced tumor necrosis and




Adult (8-12 weeks of age) female BALB/c-nu/nu mice,
bred at our research institute, were used as host animalsfor xenografted tumors. Animal care and experimental
procedures were approved by the Institutional Committee
on Research Animal Care and were performed in accord-
ance with the Interdisciplinary Principles and Guidelines
for the Use of Animals in Research, Marketing, and
Education (New York Academy of Sciences, New York,
NY, USA). The experiments were performed with tumors
of the amelanotic human melanoma A-07, established and
characterized as described previously [23]. A-07 cells were
obtained from our frozen stock and were cultured in
RPMI-1640 medium (25 mM HEPES and L-glutamine)
supplemented with 13% bovine calf serum, 250 mg/l
penicillin, and 50 mg/l streptomycin. Approximately
3.5 × 105 cells in 10 μl of Hanks’ balanced salt solution
(HBSS) were inoculated intradermally in the hind leg
by using a 100-μl Hamilton syringe. Tumor volume (V)
was calculated as V = (π/6) × a × b2, where a is the longer
and b is the shorter of two perpendicular diameters,
measured with calipers.
Sunitinib treatment
Sunitinb L-malate (LC Laboratories, Woburn, MA, USA)
was dissolved in hydrochloric acid (1.0 molar ratio of suni-
tinib). Polysorbate 80 (0.5%; Sigma-Aldrich, Schnelldorf,
Germany), polyethylene Glycol 300 (10%; Sigma-Aldrich),
sodium hydroxide (to adjust pH to 3.5), and sterile
water were added to the solution. Mice were treated
with 40 mg/kg/day sunitinib or vehicle for 4 days, by
oral administration.
Anesthesia
MRI and IFP measurements were carried out with anes-
thetized mice. Fentanyl citrate (Janssen Pharmaceutica,
Beerse, Belgium), fluanisone (Janssen Pharmaceutica), and
midazolam (Hoffmann-La Roche, Basel, Switzerland) were
administered intraperitoneally in doses of 0.63 mg/kg,
20 mg/kg, and 10 mg/kg, respectively. The body core
temperature of the mice was kept at 37-38°C during
MRI and IFP measurements by using a thermostatically
regulated heating pad.
MRI
MRI was performed by using a 1.5-T whole-body clinical
scanner (Signa; General Electric, Milwaukee, WI, USA)
and a slotted tube resonator transceiver coil constructed
for mice. The tumors were positioned in the isocenter of
the magnet and were imaged axially in a single section
through the tumor center.
DW-MRI was carried out by applying a diffusion-
weighted single-shot fast spin echo sequence with ETL =
84 and TR = 5002 ms. The diffusion weighted images were
recorded at a spatial resolution of 0.39 × 0.39 × 2.0 mm3
by using an image matrix of 256 × 256, a field of view of
10 × 10 cm2, and 5-10 excitations. Diffusion sensitization
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the following x, y, and z physical gradient combinations:
[1 0 1], [−1 0 1], [0 1 1], [0 1-1], [1 1 0], [−1 1 0]. Three
different diffusion-weightings with diffusion encoding
constants of b = 200, 400, and 800 s/mm2 and correspond-
ing echo times of TE = 85, 95.5, and 108.9 ms were used.
An image without diffusion weighting (b = 0) was recorded
for each TE value to compensate for the different TEs
associated with the different b values. The total scan
time of our DW-MRI method was ~ 10 min. ADC maps
were produced with in-house-made software developed
in Matlab. Briefly, the directional diffusion images were
averaged on a voxel-by-voxel basis to non-directional
diffusion images. ADC values were calculated for each




S b ¼ 0;TEð Þ
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¼ −b⋅ADC þ c
by using a linear least square fit algorithm. The signal
decay of a large number of voxels was investigated to
verify that the mono-exponential model gave good fits
to the data. The fits generally had a correlation coefficient
of 0.98 - 0.99.
DCE-MRI was carried out as described earlier [24].
Briefly, Gd-DTPA (Schering, Berlin, Germany), diluted
to a final concentration of 0.06 M, was administered in
the tail vein of mice in a bolus dose of 5.0 ml/kg during
a period of 5 s. Two calibration tubes, one with 0.5 mM
Gd-DTPA in 0.9% saline and the other with 0.9% saline
only, were placed adjacent to the mice in the coil. The
tumors and the calibration tubes were imaged at a spatial
resolution of 0.23 × 0.23 × 2.0 mm3 by using an image
matrix of 256 × 128, a field of view of 6 × 3 cm2, and one
excitation. Two types of spoiled gradient recalled im-
ages were recorded: proton density images (TR = 900 ms,
TE = 3.2 ms, and αPD = 20) and T1-weighted images
(TR = 200 ms, TE = 3.2 ms, and αT1 = 80). The durations
of the imaging sequences were 64 and 14 s, respectively.
Two proton density images and three T1-weighted images
were acquired before Gd-DTPA was administered. After
the administration of Gd-DTPA, T1-weighted images were
recorded every 14 s for 15 min. Gd-DTPA concentrations
were calculated from signal intensities by using the method
of Hittmair et al. [25]. The DCE-MRI series were analyzed
on a voxel-by-voxel basis by using the arterial input
function of Benjaminsen et al. [24] and the Tofts phar-
macokinetic model [16] to produce parametric images
of Ktrans.
IFP measurements
IFP was measured by using a Millar SPC 320 catheter
equipped with a 2F Micro-Tip transducer with diameter0.66 mm (Millar Instruments, Houston, TX) [26]. The
catheter was connected to a computer via a Millar
TC-510 control unit and a model 13-66150-50 pre-
amplifier (Gould Instruments, Cleveland, OH). IFP
was measured in the center of the tumors by placing
the catheter 5-10 mm from the tumor surface. Marks
on the catheter assured correct positioning of the sensor,
and a single measurement was carried out in each
tumor. Only IFP measurements with stable readings for
3-5 minutes were accepted, and the measurements lasted
for 10-20 minutes. Data acquisition was carried out by using
LabVIEW software (National Instruments, Austin, TX).
Hypoxia, necrosis, and microvessels
CD31 was used as a marker for endothelial cells and
pimonidazole [1-[(2-hydroxy-3-piperidinyl)-propyl]-2-nitro-
imidazole] was used as a hypoxia marker. Pimonidazole
was dissolved in 0.9% sodium chloride and administered
intraperitoneally at a dose of 30 mg/kg. The tumors were
resected and fixed in phosphate-buffered 4% paraformal-
dehyde approximately 4 hours after the pimonidazole
administration. Immunohistochemistry was done by using
a peroxidase-based indirect staining method [27]. An
anti-pimonidazole rabbit polyclonal antibody (gift from
Prof. J.A. Raleigh, Department of Radiation Oncology,
University of North Carolina School of Medicine, Chapel
Hill, NC) or an anti-CD31 rabbit polyclonal antibody
(Abcam, Cambridge, United Kingdom) was used as primary
antibody. Diaminobenzidine was used as chromogen, and
hematoxylin was used for counterstaining. Hypoxic fraction
was defined as the area fraction showing positive pimoni-
dazole staining (hypoxic fraction = pimonidazole positive
area/viable tissue area·100%) and necrotic fraction was
defined as the area fraction showing necrotic tissue
(necrotic fraction = necrotic tissue area/total area·100%).
The area fraction showing positive pimonidazole staining
and the area fraction showing necrotic tissue were de-
termined by image analysis. Microvascular density was
defined as the number of microvessel profiles per mm2
of viable tumor tissue (microvascular density = number
of microvessel profiles/viable tissue area). The number of
microvessel profiles was scored manually in immunohiso-
chemical preparations stained with anti-CD31 antibody.
Statistical analysis
Statistical comparisons of data were carried out by the
Student’s t test when the data complied with the conditions
of normality and equal variance. Under other conditions,
comparisons were done by nonparametric analysis using
the Mann-Whitney rank sum test. Probability values of
P < 0.05, determined from two-sided tests, were consid-
ered significant. The statistical analysis was performed
by using the SigmaStat statistical software (SPSS Science,
Chicago, IL, USA).
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A-07 tumors were divided into groups with matched
tumor sizes to receive sunitinib treatment or no treatment
(vehicle). Tumors in both groups grew during the 4-day
treatment period (Figure 1). After the treatment, suniti-
nib-treated tumors did not differ from untreated tumors
in size (Figure 1; P > 0.05), indicating that this short-term
treatment did not affect tumor growth.
Sunitinib treatment affected tumor physiology. This
is illustrated in Figure 2 which shows representative
immunohistochemical preparations stained for micro-
vessels (Figure 2A) and hypoxia (Figure 2B), and graphs
illustrating the quantification of microvascular density,
hypoxic fraction, necrotic fraction, and tumor IFP in
untreated and sunitinib-treated tumors (Figure 2C-F).
Sunitinib-treated tumors showed lower microvascular
densities (Figure 2C; P < 0.0001), higher hypoxic fractions
(Figure 2D; P = 0.045), and higher necrotic fractions
(Figure 2E; P = 0.0015) than untreated tumors. Sunitinib-
treated tumors did not differ from untreated tumors in
IFP (Figure 2F; P > 0.05).
To investigate whether MRI could detect sunitinb-
induced changes in tumor physiology, untreated and
sunitinib-treated tumors were subjected to DW-MRI
and DCE-MRI. ADC images and ADC frequency distri-
butions were produced from DW-MRI data, and Ktrans
images and Ktrans frequency distributions were produced
from DCE-MRI series. Figure 3 shows the ADC image,
the corresponding ADC frequency distribution, the Ktrans
image, and the corresponding Ktrans frequency distribution
of a representative untreated tumor (Figure 3A) and a
representative sunitinib-treated tumor (Figure 3B). Figure 4
shows average ADC and average Ktrans of 15 untreated
and 14 sunitinb-treated tumors, demonstrating that su-
nitinib-treated tumors showed significantly higher ADC
values (Figure 4A; P < 0.0001) and significantly lowerFigure 1 Sunitinib treatment did not affect tumor growth.
Tumor size before and after 4 days of treatment in mice given
vehicle (white colomns) or sunitinib (black columns). Columns,
means of 14-15 A-07 tumors, bars SEM.Ktrans values (Figure 4B; P = 0.0037) than untreated
tumors.
Discussion
Sunitinib treatment did not reduce the growth of A-07
tumors, but despite this sunitinib-treated tumors showed
altered vasculature and microenvironment and, interest-
ingly, altered ADC and Ktrans values. These observations
illustrate that sunitinib treatment affected tumor physi-
ology without affecting tumor size, and that DW-MRI
and DCE-MRI were sensitive to these early effects. The
observation that this short sunitinib treatment did not
affect tumor growth is in line with our previous experi-
ence with tumors of the same melanoma line growing in
dorsal window chambers [11]. In that study, we observed
that 4-days with sunitinib treatment did not affect tumor
growth, whereas tumor growth was reduced when the
treatment was continued for 8 days.
Treatment-induced reductions in tumor size generally
occur late after antiangiogenic treatment [5]. If non-
responding patients could be identified shortly after
treatment initiation, any ineffective treatment could be
stopped to avoid toxicity, and other treatments could
be considered. In the current study, a short treatment
period was chosen deliberately to investigate whether
DW-MRI and DCE-MRI can detect treatment-induced
effects occurring before reductions in tumor size. Our
study suggests that these MR techniques may be used to
identify patients that respond to antiangiogenic treatment
before treatment-induced reductions in tumor size can
be detected.
Sunitinib-treated tumors showed reduced Ktrans and
increased ADC values. The reduction in Ktrans could be
attributed to several vascular effects, but sunitinib-induced
reduction in microvascular density was probably the
dominating effect. We have previously shown that
Ktrans reflects vessel density in untreated A-07 tumors
[24,28], and in the current study sunitinib-treated tumors
showed significantly lower microvascular density than
untreated tumors. Sunitinib-induced inhibition of VEGFR-
2 may also have reduced vessel permeability, because
VEGF-A signaling is known to increase vessel permeability
[29]. The reduction in Ktrans may thus also be influenced
by reduced vessel permeability. The increase in ADC
was probably a result of sunitinib-induced necrosis.
Sunitinib-treated tumors showed massive necrosis whereas
untreated tumors did not show necrotic regions. Elevated
ADC values have been found in necrotic tissue in un-
treated tumors [12,13], and increases in ADC reflecting
treatment-induced necrosis have been reported after
chemotherapy, radiation therapy, and treatment with
vascular disrupting agents [6].
In the current study, DW-MRI was performed by
choosing b values of 200-800 s/mm2 to avoid confounding
Figure 2 Sunitinib treatment affected tumor physiology. A-B, representative immunohistochemical preparations stained with anti-CD31
antibody to visualize microvessels (A) or anti-pimonidazole antibody to visualize hypoxic regions (B). The images show an untreated A-07 tumor
(vehicle; left) and a sunitinib-treated A-07 tumor (sunitinib; right). C-F, microvascular density (MVD), hypoxic fraction, necrotic fraction, and IFP in
untreated and sunitinib-treated A-07 tumors. Columns, means of 11-15 tumors; bars, SEM.
Figure 3 ADC and Ktrans images. ADC image, the corresponding ADC frequency distribution, Ktrans image, and the corresponding Ktrans
frequency distribution of a representative untreated A-07 tumor (A) and a representative sunitinib-treated A-07 tumor (B). Color bars show ADC
scale in 10-3 mm2/s or Ktrans scale in min-1. Vertical line in the frequency distributions shows median ADC or median Ktrans.
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Figure 4 Sunitinib treatment increased ADC and reduced Ktrans values. ADC (A) and Ktrans (B) in untreated and sunitinib-treated A-07 tumors.
Columns, means of 14-15 tumors; bars, SEM.
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et al. [30]. It is therefore unlikely that the ADC values
reported here were significantly influenced by vascular
effects. The present study thus strongly suggests that
ADC and Ktrans reflected different physiological parameters,
illustrating that it may be beneficial to combine DW-MRI
and DCE-MRI when evaluating effects of antiangiogenic
treatment.
It has been suggested that antiangiogenic agents
including sunitininib can normalize tumor vasculature
and microenvironment and hence sensitize tumors to
conventional therapy [4,31]. Thus antiangiogenic treatment
has been shown to enhance blood perfusion, improve
oxygenation, and lower IFP in some tumor models [2,3].
In other tumor models, antiangiogenic agents have failed
to normalize the vasculature and have induced hypoxia
[10,11]. In the current study, sunitinib treatment reduced
microvascular density, increased hypoxic fraction, induced
necrosis, and did not alter IFP. Consequently, the treat-
ment schedule applied here resulted in changes in the
tumor microenvironment that argue against treatment-
induced normalization. This observation is in line with
our previous experience with A-07 and R-18 human
melanoma xenografts growing in dorsal window chambers
[11]. In that study, tumors were treated with two different
sunitinib doses and the effect was assessed multiple times
during the treatment period. The treatments did not
improve vascular function at any time point, suggesting
that sunitinib cannot normalize tumor vasculature in these
melanoma xenografts.
In tumors where antiangiogenic treatment induces hyp-
oxia, neoadjuvant antiangiogenic therapy is expected to
reduce the effect of radiation and chemotherapy [7,8].
In contrast, neoadjuvant antiangiogenic therapy has been
shown to enhance the effect of radiation or chemotherapy
in preclinical tumors where antiangiogenic treatmentnormalizes the vasculature and the microenvironment
[2,3]. The current study suggests that DW-MRI and DCE-
MRI can be used to identify tumors where antiangiogenic
treatment does not normalize the microenvironment.
These tumors respond to antiangiogenic treatment with
reduced Ktrans and increased ADC. Interestingly, in-
creased Ktrans and reduced ADC have been reported in
tumors where antiangiogenic treatment has normalized
the vasculature and the microenvironment [14,32].
Vascular normalization is a transient effect because
tumors can switch to other angiogenesis pathways and
become resistant to antiangiogenic agents. The duration
of improved tumor oxygenation is also expected to be
limited because the beneficial effects of vascular normal-
ization may be balanced by severe vascular regression after
prolonged exposure to antiangiogenic agents [31]. Winkler
et al. demonstrated that VEGFR-2 blockade enhanced the
effect of radiation when the tumors were irradiated during
the time window when the antiangiogenic agent normal-
ized the vasculature and improved oxygenation [3]. They
also showed that VEGFR-2 blockade did not enhance the
effect of radiation when tumors were irradiated before
or after this time window, suggesting that the timing of
combination therapies may be crucial to achieve maximal
antitumor effect. Previous studies suggest that DW-MRI
and DCE-MRI are sensitive to vascular normalization
[14,32], and the current study suggests that these tech-
niques are also sensitive to microenvironmental effects
that indicate no normalization. Taken together, these
studies suggest that DW-MRI and DCE-MRI may be
used to monitor the effect of antiangiogenic treatment
to identify a potential normalization window.
Conclusions
Previous studies have suggested that DW-MRI and DCE-
MRI are sensitive to vascular normalization. The current
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to treatment-induced changes in the tumor microenviron-
ment that indicate no normalization, suggesting that
these imaging techniques may be used to identify both
tumors where antiangiogenic treatment normalizes the
microenvironment and tumors where antiangiogenic
treatment does not normalize the microenvironment.
Furthermore, the current study demonstrates that DW-
MRI and DCE-MRI are sensitive to treatment-induced
changes in the tumor microenvironment that occur before
tumor size is affected, suggesting that these techniques
can predict tumor response to antiangiogenic treatment
before treatment-induced reductions in tumor size can
be detected.Competing interests
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